Cargando…
Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
Novel oral anticoagulants (NOACs) are increasingly used in clinical practice, but lack of commercially available reversal agents is a major barrier for mainstream use of these therapies. Specific antidotes to NOACs are under development. Idarucizumab (aDabi-Fab, BI 655075) is a novel humanized mouse...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762436/ https://www.ncbi.nlm.nih.gov/pubmed/26937198 http://dx.doi.org/10.2147/VHRM.S89130 |
_version_ | 1782417112162107392 |
---|---|
author | Hu, Tiffany Y Vaidya, Vaibhav R Asirvatham, Samuel J |
author_facet | Hu, Tiffany Y Vaidya, Vaibhav R Asirvatham, Samuel J |
author_sort | Hu, Tiffany Y |
collection | PubMed |
description | Novel oral anticoagulants (NOACs) are increasingly used in clinical practice, but lack of commercially available reversal agents is a major barrier for mainstream use of these therapies. Specific antidotes to NOACs are under development. Idarucizumab (aDabi-Fab, BI 655075) is a novel humanized mouse monoclonal antibody that binds dabigatran and reverses its anticoagulant effect. In a recent Phase III study (Reversal Effects of Idarucizumab on Active Dabigatran), a 5 g intravenous infusion of idarucizumab resulted in the normalization of dilute thrombin time in 98% and 93% of the two groups studied, with normalization of ecarin-clotting time in 89% and 88% patients. Two other antidotes, andexanet alfa (PRT064445) and ciraparantag (PER977) are also under development for reversal of NOACs. In this review, we discuss commonly encountered management issues with NOACs such as periprocedural management, laboratory monitoring of anticoagulation, and management of bleeding. We review currently available data regarding specific antidotes to NOACs with respect to pharmacology and clinical trials. |
format | Online Article Text |
id | pubmed-4762436 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-47624362016-03-02 Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab Hu, Tiffany Y Vaidya, Vaibhav R Asirvatham, Samuel J Vasc Health Risk Manag Review Novel oral anticoagulants (NOACs) are increasingly used in clinical practice, but lack of commercially available reversal agents is a major barrier for mainstream use of these therapies. Specific antidotes to NOACs are under development. Idarucizumab (aDabi-Fab, BI 655075) is a novel humanized mouse monoclonal antibody that binds dabigatran and reverses its anticoagulant effect. In a recent Phase III study (Reversal Effects of Idarucizumab on Active Dabigatran), a 5 g intravenous infusion of idarucizumab resulted in the normalization of dilute thrombin time in 98% and 93% of the two groups studied, with normalization of ecarin-clotting time in 89% and 88% patients. Two other antidotes, andexanet alfa (PRT064445) and ciraparantag (PER977) are also under development for reversal of NOACs. In this review, we discuss commonly encountered management issues with NOACs such as periprocedural management, laboratory monitoring of anticoagulation, and management of bleeding. We review currently available data regarding specific antidotes to NOACs with respect to pharmacology and clinical trials. Dove Medical Press 2016-02-17 /pmc/articles/PMC4762436/ /pubmed/26937198 http://dx.doi.org/10.2147/VHRM.S89130 Text en © 2016 Hu et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Hu, Tiffany Y Vaidya, Vaibhav R Asirvatham, Samuel J Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab |
title | Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab |
title_full | Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab |
title_fullStr | Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab |
title_full_unstemmed | Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab |
title_short | Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab |
title_sort | reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762436/ https://www.ncbi.nlm.nih.gov/pubmed/26937198 http://dx.doi.org/10.2147/VHRM.S89130 |
work_keys_str_mv | AT hutiffanyy reversinganticoagulanteffectsofnoveloralanticoagulantsroleofciraparantagandexanetalfaandidarucizumab AT vaidyavaibhavr reversinganticoagulanteffectsofnoveloralanticoagulantsroleofciraparantagandexanetalfaandidarucizumab AT asirvathamsamuelj reversinganticoagulanteffectsofnoveloralanticoagulantsroleofciraparantagandexanetalfaandidarucizumab |